增龄与动脉粥样硬化性心血管疾病临床类型的相关性分析

胡洁; 陈庆伟; 贺无恙

doi:10.13201/j.issn.1001-1439.2018.11.011

增龄与动脉粥样硬化性心血管疾病临床类型的相关性分析

- 重庆医科大学附属第二医院老年心血管科(重庆, 400010)
基金项目:
重庆市体育科研项目 (No:B201612)

重庆市渝中区科技计划项目 (No:2017406)

重庆市中医药科技项目 (No:ZY20150244)

重庆市卫计委医学科研面上项目 (No:2017MSXM038)

详细信息

通讯作者: 陈庆伟,E-mail:chengwcq@163.com

中图分类号: R54

收稿日期: 2018-07-08

Relationship between aging and comorbid clinical classifications of atherosclerotic cardiovascular disease

- Department of Geriatrics Cardiology, The Second Hospital Affiliated to Chongqing Medical University, Chongqing, 400010, China

More Information

Corresponding author: CHEN Qingwei, E-mail: chengwcq@163.com

Received Date: 08 July 2018

摘要

摘要: 目的:探讨增龄与动脉粥样硬化性心血管疾病(ASCVD)临床类型及其他心血管病危险因素的相关性。方法:连续入选重庆医科大学附属第二医院老年心血管科2016-07-2017-07入院患者1 014例。根据ASCVD临床类型将患者分为3组:A组:非ASCVD组(130例);B组:ASCVD单一临床类型组(334例),包括缺血性卒中126例、冠心病154例、外周动脉疾病(PAD)54例;C组:ASCVD多种临床类型并发组(550例),包括缺血性卒中合并冠心病147例、缺血性卒中合并PAD 116例、冠心病合并PAD 145例、卒中合并PAD及冠心病142例。比较各组间临床指标的差异,并通过多因素Logistic回归模型探索ASCVD多种临床类型并发的危险因素,进一步采用相关分析研究增龄与其他ASCVD危险因素的相关性。结果:C组患者的年龄较B组升高[(76.49±8.07)岁∶(70.20±9.02)岁,P<0.01]。多因素二元Logistic回归分析校正心血管病常见危险因素后提示:增龄(OR=1.059,95%CI:1.038~1.080)、颈总动脉内膜-中层厚度(cIMT)(OR=15.177,95%CI:4.369~52.723)、吸烟(OR=2.472,95%CI:1.709~3.576)、糖尿病(OR=1.890,95%CI:1.273~2.806)、血清肌酐(Cr)(OR=1.028,95%CI:1.019~1.037)、脉压差(PP)(OR=1.029,95%CI:1.011~1.048)均与ASCVD多种临床类型的合并发生独立相关。双变量Spearman相关分析及偏相关分析结果显示,增龄与cIMT、Cr、PP呈显著正相关性(均P<0.01)。结论:增龄与cIMT、Cr、PP对ASCVD多种临床类型的并发具有协同作用。随着年龄的增长,ASCVD多种临床类型并发的风险增加,需及早开始监测相关风险指标。
- 动脉粥样硬化性心血管疾病 /
- 年龄 /
- 危险因素 /
- 临床类型
Abstract: Objective:To explore the relationship between the increasement of age and clinical classifications of atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular risk factors.Method:A total of 1 014 patients admitted in our hospital from 2016-07 to 2017-07 were enrolled.According to the clinic classification of ASCVD,all patients were divided into 3 groups:Group A (n=130),patients without ASCVD;Group B (n=334),patients with one of the following disease:stroke,coronary artery disease (CAD) or peripheral artery disease (PAD);Group C (n=550),patients with ischemia stroke+CAD,stroke+PAD,CAD+PAD or stroke+CAD+PAD.Firstly,the baseline clinical data among 3 groups were compared.Then,risk factors for multiple clinic classifications of ASCVD were explored by binary Logistic regression analysis.Besides,the correlation between age and other risk factors were analyzed.Result:Patients in group C were older than those in group B [(76.49±8.07) years vs (70.20±9.02) years,P<0.01].Multivariate Logistic regression analysis suggested that ageing (OR=1.059,95%CI:1.038-1.080),cIMT (OR=15.177,95%CI:4.369~52.723),smoking (OR=2.472,95%CI:1.709-3.576),diabetes (OR=1.890,95%CI:1.273-2.806),Cr (OR=1.028,95%CI:1.019-1.037),and PP (OR=1.029,95%CI:1.011-1.048) were independently associated with multiple clinical classifications of ASCVD.Bivariate Spearman correlation analysis and partial correlation analysis showed that ageing was significantly positively correlated with cIMT,Cr,and PP (all P<0.01).Conclusion:Age,cIMT,Cr and PP have synergistic effects on the development of multiple clinical classifications of ASCVD.The risk of comorbid clinical classifications of ASCVD increases with age.It is necessary to start monitoring relevant risk indicators as early as possible.
- atherosclerotic cardiovascular disease /
- age /
- risk factors /
- clinical classifications

HTML全文

参考文献(18)

[1]	Ellulu MS, Patimah I, Khaza'ai H, et al.Atherosclerotic cardiovascular disease:a review of initiators and protective factors[J].Inflammopharmacology, 2016, 24 (1):1-10.
[2]	Conte SM, Vale PR.Peripheral Arterial Disease[J].Heart Lung Circ, 2018, 27 (4):427-432.
[3]	Bertomeu V, Morillas P, Gonzalez-Juanatey JR, et al.Prevalence and prognostic influence of peripheral arterial disease in patients>or=40years old admitted into hospital following an acute coronary event[J].EurJ Vasc Endovasc Surg, 2008, 36 (2):189-196.
[4]	徐燕军, 赵俊功.周围血管疾病合并冠心病的研究进展[J].介入放射学杂志, 2016, 25 (1):85-88.
[5]	O'Neal WT, Efird JT, Nazarian S, et al.Peripheral arterial disease and risk of atrial fibrillation and stroke:the Multi-Ethnic Study of Atherosclerosis[J].J Am Heart Assoc, 2014, 3 (6):e001270.
[6]	苏暄.CIT2016:冠心病合并脑卒中等疑难问题的介入治疗策略[J].中国医药科学, 2016, 6 (9):6-8.
[7]	Jacobson TA, Ito MK, Maki KC, et al.National lipid association recommendations for patient-centered management of dyslipidemia:part 1——full report[J].J Clin Lipidol, 2015, 9 (2):129-169.
[8]	中华医学会神经病学分会.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志, 2015, 48 (4):246-257.
[9]	Creager MA, Belkin M, Bluth EI, et al.2012 ACCF/AHA/ACR/SCAI/SIR/STS/SVM/SVN/SVSkey data elements and definitions for peripheral atherosclerotic vascular disease:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Peripheral Atherosclerotic Vascular Disease)[J].Circulation, 2012, 125 (2):395-467.
[10]	张维臣, 顾蓉, 魏钟海, 等.体质指数对心脏再同步化治疗患者远期预后的影响[J].临床心血管病杂志, 2017, 33 (3):230-234.
[11]	刘力生.中国高血压防治指南2010[J].中华高血压杂志, 2011, 3 (8):42-93.
[12]	Mays L.Diabetes mellitus standards of care[J].Nurs Clin North Am, 2015, 50 (4):703-711.
[13]	Yang X, Li J, Hu D, et al.Predicting the 10-year risks of atherosclerotic cardiovascular disease in chinese population:The China-PAR Project (Prediction for ASCVD Risk in China)[J].Circulation, 2016, 134 (19):1430-1440.
[14]	Yakubov S.Polyvascular atherosclerotic disease:recognizing the risks and managing the syndrome[J].Curr Med Res Opin, 2009, 25 (11):2631-2641.
[15]	Stone NJ, Robinson JG, Lichtenstein AH, et al.2013ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J].J Am Coll Cardiol, 2014, 63 (25Pt B):2889-2934.
[16]	Suarez C, Zeymer U, Limbourg T, et al.Influence of polyvascular disease on cardiovascular event rates.Insights from the REACH Registry[J].Vasc Med, 2010, 15 (4):259-265.
[17]	杨佳, 刘增长.颈动脉病变与冠状动脉病变关系的探讨[J].临床心血管病杂志, 2016, 32 (2):143-147.
[18]	Kienitz T, Quinkler M.Testosterone and blood pressure regulation[J].Kidney Blood Press Res, 2008, 31 (2):71-79.